Prevalence of NASH/NAFLD in people with obesity who are currently classified as metabolically healthy.


Journal

Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
ISSN: 1878-7533
Titre abrégé: Surg Obes Relat Dis
Pays: United States
ID NLM: 101233161

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 24 03 2020
revised: 28 06 2020
accepted: 03 07 2020
pubmed: 14 8 2020
medline: 28 4 2021
entrez: 14 8 2020
Statut: ppublish

Résumé

While metabolic health in obesity may confer a protective status, recent studies indicate that nonalcoholic fatty liver disease (NAFLD) or even nonalcoholic steatohepatitis (NASH) may exist in this category of individuals. Although cardiovascular and diabetic risks have been well described, the risk of NAFLD and NASH among this population requires further investigation. Our goal was to compare the prevalence of steatosis, NAFLD, and NASH between individuals with metabolically healthy obesity (MHO) and individuals with metabolically abnormal obesity (MAO) and to identify preoperative risk factors for these conditions in a prospective cohort with morbid obesity scheduled for bariatric surgery. Tertiary referral university hospital in France. The prospective cohort included 837 bariatric patients who also had an intraoperative liver biopsy between 2002 and 2015. Obese individuals fulfilling none of the criteria in the strict definition of metabolic syndrome were considered metabolically healthy. Preoperative blood samples and liver pathology examinations were reviewed. Steatosis, NAFLD, and NASH were carefully identified allowing comparison of prevalence and risk factors between the 2 cohorts. In total, 149 patients (17.8%) had MHO and the remaining 688 (82.2%) had MAO. The cohort with MHO was significantly younger, had a significantly lower glycosylated hemoglobin, a lower homeostasis model assessment of insulin resistance, and increased C-reactive protein. In individuals with MHO, 44 patients (29.5%) had at least moderate steatosis (>33% macrovesicular steatosis) and 5.4% had NASH. Using logistic regression, waist circumference was positively associated with NASH, whereas body mass index and alanine aminotransferase were significantly associated with severe steatosis (>66%). Our study indicates that obese individuals without metabolic syndrome may develop subclinical liver involvement. Therefore, the occurrence of NAFLD and NASH in this population needs further investigation.

Sections du résumé

BACKGROUND BACKGROUND
While metabolic health in obesity may confer a protective status, recent studies indicate that nonalcoholic fatty liver disease (NAFLD) or even nonalcoholic steatohepatitis (NASH) may exist in this category of individuals. Although cardiovascular and diabetic risks have been well described, the risk of NAFLD and NASH among this population requires further investigation.
OBJECTIVE OBJECTIVE
Our goal was to compare the prevalence of steatosis, NAFLD, and NASH between individuals with metabolically healthy obesity (MHO) and individuals with metabolically abnormal obesity (MAO) and to identify preoperative risk factors for these conditions in a prospective cohort with morbid obesity scheduled for bariatric surgery.
SETTINGS METHODS
Tertiary referral university hospital in France.
METHODS METHODS
The prospective cohort included 837 bariatric patients who also had an intraoperative liver biopsy between 2002 and 2015. Obese individuals fulfilling none of the criteria in the strict definition of metabolic syndrome were considered metabolically healthy. Preoperative blood samples and liver pathology examinations were reviewed. Steatosis, NAFLD, and NASH were carefully identified allowing comparison of prevalence and risk factors between the 2 cohorts.
RESULTS RESULTS
In total, 149 patients (17.8%) had MHO and the remaining 688 (82.2%) had MAO. The cohort with MHO was significantly younger, had a significantly lower glycosylated hemoglobin, a lower homeostasis model assessment of insulin resistance, and increased C-reactive protein. In individuals with MHO, 44 patients (29.5%) had at least moderate steatosis (>33% macrovesicular steatosis) and 5.4% had NASH. Using logistic regression, waist circumference was positively associated with NASH, whereas body mass index and alanine aminotransferase were significantly associated with severe steatosis (>66%).
CONCLUSION CONCLUSIONS
Our study indicates that obese individuals without metabolic syndrome may develop subclinical liver involvement. Therefore, the occurrence of NAFLD and NASH in this population needs further investigation.

Identifiants

pubmed: 32788075
pii: S1550-7289(20)30411-1
doi: 10.1016/j.soard.2020.07.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2050-2057

Informations de copyright

Copyright © 2020 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Sébastien Frey (S)

Université Côte d'Azur, Nice, France; Department of Digestive surgery and liver transplantation, Archet 2 Hospital, University Hospital of Nice, Nice, France.

Stéphanie Patouraux (S)

Université Côte d'Azur, Nice, France; Department of Pathology, Pasteur Hospital, University Hospital of Nice, Nice, France.

Tarek Debs (T)

Department of Digestive surgery and liver transplantation, Archet 2 Hospital, University Hospital of Nice, Nice, France.

Jean Gugenheim (J)

Université Côte d'Azur, Nice, France; Department of Digestive surgery and liver transplantation, Archet 2 Hospital, University Hospital of Nice, Nice, France; Inserm, U1065, Team 8 "Hepatic complications of obesity and alcohol," Nice, France.

Rodolphe Anty (R)

Université Côte d'Azur, Nice, France; Inserm, U1065, Team 8 "Hepatic complications of obesity and alcohol," Nice, France; Department of Hepathology, Archet 2 Hospital, University Hospital of Nice, Nice, France.

Antonio Iannelli (A)

Université Côte d'Azur, Nice, France; Department of Digestive surgery and liver transplantation, Archet 2 Hospital, University Hospital of Nice, Nice, France; Department of Hepathology, Archet 2 Hospital, University Hospital of Nice, Nice, France. Electronic address: iannelli.a@chu-nice.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH